Eyepoint Pharmaceuticals’ (EYPT) “Sell (D-)” Rating Reiterated at Weiss Ratings

Eyepoint Pharmaceuticals (NASDAQ:EYPT)‘s stock had its “sell (d-)” rating reissued by research analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Several other equities research analysts have also commented on the stock. Royal Bank Of Canada started coverage on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, June 17th. They set an “outperform” rating and a $28.00 price objective on the stock. Chardan Capital reissued a “buy” rating and set a $27.00 price objective on shares of Eyepoint Pharmaceuticals in a research note on Thursday, August 7th. Finally, HC Wainwright boosted their price objective on shares of Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday, August 6th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Eyepoint Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $26.86.

Eyepoint Pharmaceuticals Price Performance

Shares of NASDAQ EYPT opened at $13.88 on Wednesday. Eyepoint Pharmaceuticals has a 1 year low of $3.91 and a 1 year high of $14.91. The company’s 50-day moving average is $12.31 and its 200 day moving average is $9.19. The stock has a market capitalization of $956.75 million, a P/E ratio of -5.18 and a beta of 1.95.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.18). Eyepoint Pharmaceuticals had a negative net margin of 337.93% and a negative return on equity of 63.80%. The company had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $6.82 million. Research analysts anticipate that Eyepoint Pharmaceuticals will post -2.13 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in EYPT. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Eyepoint Pharmaceuticals by 31.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 90,349 shares of the company’s stock valued at $673,000 after purchasing an additional 21,719 shares during the last quarter. California State Teachers Retirement System raised its holdings in shares of Eyepoint Pharmaceuticals by 3.8% during the fourth quarter. California State Teachers Retirement System now owns 48,614 shares of the company’s stock valued at $362,000 after purchasing an additional 1,797 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Eyepoint Pharmaceuticals by 3,174.4% during the first quarter. GAMMA Investing LLC now owns 10,249 shares of the company’s stock valued at $56,000 after purchasing an additional 9,936 shares during the last quarter. Cyndeo Wealth Partners LLC raised its holdings in shares of Eyepoint Pharmaceuticals by 48.6% during the first quarter. Cyndeo Wealth Partners LLC now owns 25,250 shares of the company’s stock valued at $137,000 after purchasing an additional 8,260 shares during the last quarter. Finally, Deltec Asset Management LLC raised its holdings in shares of Eyepoint Pharmaceuticals by 49.3% during the first quarter. Deltec Asset Management LLC now owns 30,300 shares of the company’s stock valued at $164,000 after purchasing an additional 10,000 shares during the last quarter. 99.41% of the stock is owned by hedge funds and other institutional investors.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.